Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: Results of the enoxaparin versus tinzaparin (EVET) trial at 6 months

In patients with NSTACS, enoxaparin significantly reduced the rates of recurrent ischemic events and therapeutic procedures in the short term, with sustained benefit at 6 m compared to tinzaparin.